Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
IFRX 
InflaRx N.V. (IFRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/10/2025: IFRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.27
1 Year Target Price $11.27
| 5 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -69.96% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 71.13M USD | Price to earnings Ratio - | 1Y Target Price 11.27 |
Price to earnings Ratio - | 1Y Target Price 11.27 | ||
Volume (30-day avg) 7 | Beta 1.47 | 52 Weeks Range 0.71 - 2.77 | Updated Date 12/10/2025 |
52 Weeks Range 0.71 - 2.77 | Updated Date 12/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.71 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Earnings Date
Report Date 2025-11-26 | When - | Estimate -0.1511 | Actual -0.18 |
Profitability
Profit Margin - | Operating Margin (TTM) -42015.19% |
Management Effectiveness
Return on Assets (TTM) -40.69% | Return on Equity (TTM) -72.49% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 20974924 | Price to Sales(TTM) 1132.01 |
Enterprise Value 20974924 | Price to Sales(TTM) 1132.01 | ||
Enterprise Value to Revenue 286.76 | Enterprise Value to EBITDA 0.5 | Shares Outstanding 67747130 | Shares Floating 56928591 |
Shares Outstanding 67747130 | Shares Floating 56928591 | ||
Percent Insiders 6.38 | Percent Institutions 27.51 |
Upturn AI SWOT
InflaRx N.V.
Company Overview
History and Background
InflaRx N.V. is a biopharmaceutical company founded in 2007. It focuses on developing novel therapeutics for inflammatory diseases. A significant milestone was its IPO on the Nasdaq Global Select Market in 2017. The company has advanced its lead drug candidate through clinical trials.
Core Business Areas
- Biopharmaceutical Development: InflaRx N.V. is primarily engaged in the discovery, development, and commercialization of proprietary anti-inflammatory therapeutics. Its core business revolves around its lead drug candidate and pipeline of molecules targeting inflammatory conditions.
Leadership and Structure
InflaRx N.V. is led by a management team with experience in pharmaceutical development and commercialization. The organizational structure is typical for a clinical-stage biopharmaceutical company, with departments focused on R&D, clinical operations, regulatory affairs, and corporate functions.
Top Products and Market Share
Key Offerings
- XAV-101 (Vilobelimab): Vilobelimab is a monoclonal antibody that inhibits the complement factor C5a. It is being developed for various inflammatory diseases, including ANCA-associated vasculitis and pyoderma gangrenosum. As of recent reports, specific market share data for vilobelimab is not readily available as it is still in late-stage clinical development and seeking regulatory approval in key markets. Competitors in the C5 inhibition space include Soliris (eculizumab) and Ultomiris (ravulizumab) from Alexion (AstraZeneca), and potentially other investigational therapies targeting the complement cascade or specific inflammatory pathways.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly in the immunology and inflammation space, is characterized by significant R&D investment, lengthy clinical trial processes, and a highly competitive landscape. Companies are focused on developing targeted therapies for unmet medical needs, with a growing emphasis on precision medicine and biologics.
Positioning
InflaRx N.V. positions itself as a biopharmaceutical company focused on addressing severe inflammatory diseases with novel mechanisms of action. Its competitive advantage lies in its proprietary technology platform and its lead drug candidate's potential to address significant unmet needs in specific patient populations. However, it faces competition from established players with approved therapies and other emerging biotechs.
Total Addressable Market (TAM)
The TAM for inflammatory diseases is vast and includes conditions like autoimmune disorders, dermatological conditions, and other systemic inflammatory syndromes. For specific indications like ANCA-associated vasculitis, the TAM represents a multi-billion dollar market. InflaRx N.V. aims to capture a significant portion of this market with its targeted therapies, but its current market penetration is zero as its lead product is not yet commercialized.
Upturn SWOT Analysis
Strengths
- Proprietary technology platform for developing anti-inflammatory therapeutics.
- Lead drug candidate (Vilobelimab) with promising clinical data in specific indications.
- Experienced management team with biopharmaceutical development expertise.
- Focus on addressing significant unmet medical needs in inflammatory diseases.
Weaknesses
- Late-stage clinical development of lead product, implying high R&D costs and regulatory risks.
- Limited product pipeline compared to larger pharmaceutical companies.
- Reliance on a single lead drug candidate for significant revenue generation.
- Need for substantial capital for ongoing clinical trials and potential commercialization.
Opportunities
- Potential for regulatory approval and commercialization of Vilobelimab in multiple indications.
- Expansion of the pipeline through internal R&D or strategic partnerships.
- Growing understanding of inflammatory pathways creating new therapeutic targets.
- Acquisition or licensing opportunities by larger pharmaceutical companies.
Threats
- Clinical trial failures or unexpected safety issues.
- Intense competition from established and emerging biopharmaceutical companies.
- Stringent regulatory approval processes and potential delays.
- Pricing pressures and reimbursement challenges for novel therapies.
- Patent expirations and generic competition for existing treatments.
Competitors and Market Share
Key Competitors
- Alexion Pharmaceuticals (now AstraZeneca) (US Stock Symbol: AZN)
- Horizon Therapeutics (US Stock Symbol: HZNP - acquired by Amgen)
- UCB S.A. (US Stock Symbol: UCB.PA)
Competitive Landscape
InflaRx N.V. faces strong competition from established biopharmaceutical companies with approved therapies in the inflammatory disease space. Its advantage lies in its novel mechanism of action and focus on specific unmet needs, but it must overcome the challenges of late-stage clinical development and market entry against well-resourced competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by the progression of its drug candidates through clinical development stages, supported by equity financing. Revenue growth has been negligible.
Future Projections: Future projections are heavily dependent on the successful clinical development and regulatory approval of Vilobelimab. Analyst estimates would focus on potential peak sales for its target indications and the commercialization timeline.
Recent Initiatives: Recent initiatives likely involve advancing Vilobelimab through Phase III clinical trials, engaging with regulatory authorities, and preparing for potential commercial launch. This may also include efforts to secure additional funding or strategic collaborations.
Summary
InflaRx N.V. is a biopharmaceutical company with a promising lead drug candidate, Vilobelimab, targeting inflammatory diseases. Its strengths lie in its innovative technology and focus on unmet medical needs. However, it faces significant risks associated with late-stage clinical development, regulatory hurdles, and intense competition. Success hinges on the successful approval and commercialization of Vilobelimab, requiring substantial capital investment and strategic execution to navigate the complex pharmaceutical market.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Industry reports
- Financial news outlets
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. Data is based on publicly available information and may not be exhaustive or entirely up-to-date. Investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About InflaRx N.V.
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2017-11-08 | Co-Founder, CEO & Executive Director Dr. Niels C. Riedemann M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 74 | Website https://www.inflarx.de |
Full time employees 74 | Website https://www.inflarx.de | ||
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.